Brii Biosciences Limited

SEHK:2137 Stock Report

Market Cap: HK$817.4m

Brii Biosciences Future Growth

Future criteria checks 0/6

Brii Biosciences is forecast to grow earnings and revenue by 29.5% and 65.4% per annum respectively while EPS is expected to grow by 37% per annum.

Key information

29.5%

Earnings growth rate

37.0%

EPS growth rate

Biotechs earnings growth34.6%
Revenue growth rate65.4%
Future return on equityn/a
Analyst coverage

Low

Last updated23 May 2024

Recent future growth updates

Recent updates

Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Nov 19
Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Jul 26
Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

Jan 12
Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Sep 20
We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Mar 24
We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Earnings and Revenue Growth Forecasts

SEHK:2137 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026316-191N/AN/A1
12/31/2025181-412N/AN/A1
12/31/2024N/A-528N/AN/A1
12/31/202356-175-644-594N/A
9/30/202395-251-682-588N/A
6/30/2023134-327-720-581N/A
3/31/2023128-405-678-539N/A
12/31/2022122-484-636-496N/A
9/30/202299-1,021-591-521N/A
6/30/202275-1,558-546-546N/A
3/31/202284-2,861-713-713N/A
12/31/202193-4,164-880-879N/A
9/30/2021100-3,999-838-837N/A
6/30/2021107-3,835-796-794N/A
3/31/202194-2,512-600-599N/A
12/31/202082-1,190-404-404N/A
12/31/201920-521-91-67N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2137 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2137 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2137 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2137 is forecast to have no revenue next year.

High Growth Revenue: 2137 is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2137's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.